Telix Pharmaceuticals

Telix Pharmaceuticals (TLX AU): Stepping Ahead with First Product Approved in the U.S.

Equity Bottom-Up
229 Views, 09 Jan 2022 00:44
EXECUTIVE SUMMARY
  • Last month, Telix Pharmaceuticals (TLX AU) received FDA approval for its first cancer imaging product, Illuccix. Commercial launch of Illuccix will be the major milestone for the company in 2022.
  • EU approval for Illucix is expected in March. Illuccix has multi-billion-dollar global market opportunity, driven by rising incidence of prostate cancer, increasing clinical adoption, and geography expansion.
  • The company has a rich pipeline targeting seven indications, having high unmet medical needs. Telix is expected to file for kidney cancer imaging product, TLX250-CDx in early 2022.
detail (3-minute read)
WHAT’S TRENDING
logo
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare compa... 

x